News Merck & Co's Keytruda fails in triple negative breast cancer... Most of the time, Merck & Co’s Keytruda (pembrolizumab) has been a consistent performer across a range of cancers – but it has produced an uncharacteristic failure in tough to treat tri
News BMS and Infinity aim to overcome triple negative breast canc... BMS is looking to get ahead of its rival Merck & Co. by overcoming resistance to PD-1 immunotherapy in triple negative breast cancer patients.